Post-traumatic stress disorder is not simply a psychological condition — it is a neurological one. Trauma physically reorganizes the brain, altering the structure and function of regions responsible for fear processing, memory consolidation, and emotional regulation. Understanding PTSD as a disorder of neural circuitry helps explain why conventional treatments often fall short, and why ketamine — a medication that directly promotes neural plasticity — is emerging as a powerful therapeutic option for trauma survivors.

The Neurology of Trauma: What PTSD Does to the Brain

Brain imaging studies have revealed consistent structural and functional changes in patients with PTSD. Three regions are particularly affected:

  • Amygdala hyperactivation: The amygdala, the brain's threat detection center, becomes chronically overactive in PTSD. It fires alarm signals in response to stimuli that are objectively safe but resemble some aspect of the original trauma. This hypervigilance drives the flashbacks, nightmares, and exaggerated startle responses that characterize the disorder.
  • Prefrontal cortex suppression: The medial prefrontal cortex normally acts as a brake on the amygdala, providing top-down regulation that allows rational assessment of potential threats. In PTSD, this region shows reduced activity and volume, diminishing the brain's ability to modulate fear responses. Patients cannot simply "think their way out" of a trauma reaction because the neural hardware for doing so has been compromised.
  • Hippocampal atrophy: The hippocampus, essential for contextualizing memories in time and place, shrinks in PTSD. This atrophy contributes to the "timeless" quality of traumatic memories — the feeling that the trauma is happening right now rather than being a past event. The brain literally cannot file the memory properly.

These changes are not character flaws or failures of resilience. They are measurable biological alterations that help explain why PTSD is so persistent and why treating it effectively requires interventions that reach the neural level.

Why Traditional PTSD Treatments Have Limitations

Current first-line treatments for PTSD include SSRIs (sertraline and paroxetine are the only two FDA-approved medications for PTSD), prolonged exposure therapy, cognitive processing therapy, and EMDR (eye movement desensitization and reprocessing). These approaches help many patients, but the outcomes data reveals significant gaps.

SSRIs produce only modest symptom reduction in PTSD, with response rates of approximately 40–60% and remission rates considerably lower. Many patients experience partial improvement that leaves them still significantly impaired. The medications take 4–8 weeks to reach full effect, and for patients with acute suicidal ideation or severe functional impairment, this delay can be dangerous.

Trauma-focused psychotherapies (prolonged exposure and cognitive processing therapy) show stronger efficacy, with response rates of 50–70%. However, they require patients to engage directly with traumatic material over multiple sessions, and dropout rates are notably high — estimated at 20–40% — because the process itself can be acutely distressing. EMDR shows similar efficacy but faces the same engagement challenges.

For patients who do not respond to these approaches, or who cannot tolerate the process of trauma-focused therapy, treatment options narrow considerably. This is where ketamine enters the conversation.

How Ketamine Disrupts Fear Memory Consolidation

Ketamine's mechanism of action addresses PTSD at the level where the disorder operates: neural circuitry. As an NMDA receptor antagonist, ketamine blocks a specific glutamate receptor type that plays a central role in the consolidation and reconsolidation of fear memories.

When traumatic memories are activated, they temporarily enter a labile state where they can be modified before being re-stored. NMDA receptors are essential for this reconsolidation process. By blocking NMDA receptors during or shortly after memory activation, ketamine may disrupt the re-encoding of traumatic memories, weakening their emotional intensity without erasing the factual content.

Beyond memory reconsolidation, ketamine promotes rapid synaptogenesis — the formation of new synaptic connections — particularly in the prefrontal cortex. For PTSD patients, this means strengthening the neural circuits responsible for fear regulation and emotional control. The prefrontal cortex regains its capacity to modulate amygdala activity, restoring the brain's ability to distinguish genuine threats from trauma-associated triggers.

Neural Plasticity in Trauma-Affected Circuits

The BDNF (brain-derived neurotrophic factor) surge triggered by ketamine is particularly relevant in PTSD. BDNF promotes neuronal survival and growth in the hippocampus and prefrontal cortex — precisely the regions where PTSD causes atrophy. By stimulating growth in these areas, ketamine may help reverse some of the structural damage that chronic PTSD inflicts on the brain.

Additionally, ketamine's effects on the default mode network (DMN) — the brain system active during self-referential thinking and rumination — may help interrupt the repetitive, intrusive thought patterns that dominate the PTSD experience. Many patients report that after ketamine treatment, traumatic memories feel more distant and less emotionally overwhelming, as if the volume has been turned down on the fear response.

Key Clinical Trials: The Evidence Base

The clinical evidence for ketamine in PTSD, while newer than the depression data, is compelling and growing rapidly:

  • Feder et al. (2014): This landmark randomized controlled trial published in JAMA Psychiatry demonstrated that a single IV ketamine infusion produced significant and rapid reduction in PTSD symptoms compared to an active placebo (midazolam). Improvement was evident within 24 hours and persisted for up to two weeks after a single treatment.
  • Feder et al. (2021): A follow-up study using repeated ketamine infusions (six infusions over two weeks) showed sustained improvement in PTSD symptoms, with response rates significantly exceeding the control group. The repeated dosing protocol produced larger and more durable effects than single infusions.
  • Albott et al. (2018): A study specifically examining IV ketamine in combat veterans with PTSD found significant reductions in PTSD symptom severity, with effects emerging within days and persisting through follow-up.

Veteran and Military Populations

The military and veteran community has been a particular focus of ketamine PTSD research, in part because PTSD rates are disproportionately high in this population and because treatment resistance is common. Studies in veteran populations have consistently shown that ketamine can produce rapid symptom improvement even in patients who have not responded to multiple prior treatments.

This is especially relevant for suicidal ideation in PTSD patients. Veterans with PTSD are at significantly elevated risk for suicide, and ketamine's ability to rapidly reduce suicidal thoughts — often within hours — makes it uniquely valuable in this population. No other currently available medication can match this speed of anti-suicidal effect.

The Treatment Protocol for PTSD

At LUMUS, the ketamine protocol for PTSD follows the evidence-based approach of six IV infusions over a two-to-three-week period. Each infusion delivers a subanesthetic dose (typically 0.5 mg/kg) over approximately 40 minutes, with continuous medical monitoring throughout.

The protocol for PTSD patients includes several considerations specific to trauma:

  • Environment optimization: The clinical environment is carefully controlled to minimize potential triggers. Lighting, sound, and the overall atmosphere are designed to promote safety and calm.
  • Pre-infusion grounding: Before each session, patients work with the clinical team to establish grounding techniques they can use during the infusion if they experience distressing thoughts or imagery.
  • Dosage titration: The dissociative properties of ketamine require careful management in trauma patients. Dosing is adjusted to achieve therapeutic benefit while minimizing the risk of distressing dissociative experiences.
  • Post-infusion processing: After each infusion, patients have dedicated time to process their experience with clinical support before leaving the office.

Integration with Therapy: Amplifying the Window

One of the most promising aspects of ketamine for PTSD is its potential to enhance the effectiveness of trauma-focused psychotherapy. The enhanced neural plasticity that ketamine creates opens a therapeutic window during which the brain is more receptive to new learning and the restructuring of traumatic memories.

Several research groups are exploring "ketamine-assisted psychotherapy" protocols in which psychotherapy sessions are timed to coincide with the period of peak neuroplasticity following ketamine infusions. Early results suggest that this combination approach may produce larger and more durable improvements than either intervention alone.

At LUMUS, we coordinate with patients' existing therapists to optimize the timing of therapy sessions relative to ketamine infusions. For patients not currently in therapy, we can provide referrals to trauma-specialized therapists in the Inland Empire who are familiar with the ketamine-assisted approach.

Serving Military Families Near March ARB

LUMUS is located in Corona, California, in close proximity to March Air Reserve Base and the broader military community of the Inland Empire. We understand the unique challenges that service members, veterans, and military families face when dealing with PTSD, and we have designed our clinical approach with this population in mind.

Dr. Garcia's evaluation process accounts for the specific presentations of military-related PTSD, including combat trauma, military sexual trauma, and the complex PTSD that often develops from repeated deployments. His dual board certification in psychiatry and addiction medicine is particularly relevant, as substance use disorders frequently co-occur with PTSD in the veteran population and require careful clinical management during ketamine treatment.

Looking Forward

PTSD is a disorder of neural circuitry, and ketamine is a medication that directly repairs and reorganizes neural circuits. This mechanistic alignment explains the clinical results: rapid symptom improvement in patients for whom other treatments have provided inadequate relief. While research continues to refine protocols and identify the patients most likely to benefit, the existing evidence supports ketamine as a meaningful addition to the PTSD treatment toolkit.

If you or someone you care about is living with PTSD that has not responded adequately to conventional treatment, we encourage you to explore whether ketamine therapy might be an appropriate next step. Recovery from trauma is possible, and for many patients, ketamine provides the neurological foundation on which that recovery can be built.